Biomarker detects severe COVID-19 early on
2021
University of Zurich, Zurich, Switzerland
Disease progression in COVID-19 varies among patients infected with the SARS-CoV-2 virus. While most patients experience harmless symptoms, some patients suffer from severe illness. To assess whether the immune profile of ICU COVID-patients is specific for SARS-CoV-2 or is driven by a general inflammation also seen in non-SARS-CoV-2 pneumonia, blood samples from both kinds of patients and controls were taken. The samples were analyzed via longitudinal, high-dimensional single-cell spectral cytometry and algorithm-guided analysis to characterize their immune pattern. Results show that, besides some similarities in immune profile, in SARS-CoV-2 infections a special sort of T killer cells can serve as a predictive biomarker to assess the severeness of the disease even at an early point of time, leading to better monitoring and care of the patients.
Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia
Burkhard Becher
Added on: 05-17-2022
[1] www.cell.com/immunity/fulltext/S1074-7613(21)00208-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1074761321002089%3Fshowall%3Dtrue#%20[2] https://www.bionity.com/en/news/1171006/biomarker-detects-severe-covid-19-early-on.html
